Inhibikase Therapeutics (IKT)
NASDAQ:IKT
Total Valuation
Inhibikase Therapeutics has a market cap or net worth of $229.74M. The enterprise value is -$15.68M.
Market Cap$229.74M
Enterprise Value-$15.68M
Share Statistics
Inhibikase Therapeutics has 132,032,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding132,032,640
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Inhibikase Therapeutics’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -26.57%.
Return on Equity (ROE)-0.28
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-26.57%
Return on Capital Employed (ROCE)-0.27
Revenue Per Employee0.00
Profits Per Employee-3.22M
Employee Count15
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Inhibikase Therapeutics is ―. Inhibikase Therapeutics’s PEG ratio is 0.07.
PE Ratio―
PS Ratio0.00
PB Ratio1.17
Price to Fair Value1.17
Price to FCF-7.25
Price to Operating Cash Flow-6.23
PEG Ratio0.07
Income Statement
In the last 12 months, Inhibikase Therapeutics had revenue of 0.00 and earned -48.26M in profits. Earnings per share was -0.49.
Revenue0.00
Gross Profit-60.50K
Operating Income-45.95M
Pretax Income-48.26M
Net Income-48.26M
EBITDA-45.89M
Earnings Per Share (EPS)-0.49
Cash Flow
In the last 12 months, operating cash flow was -27.79M and capital expenditures -452.02K, giving a free cash flow of -28.24M billion.
Operating Cash Flow-27.79M
Free Cash Flow-28.24M
Free Cash Flow per Share-0.21
Dividends & Yields
Inhibikase Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.57
52-Week Price Change-7.94%
50-Day Moving Average1.78
200-Day Moving Average1.70
Relative Strength Index (RSI)46.97
Average Volume (3m)132.72K
Important Dates
Inhibikase Therapeutics upcoming earnings date is May 18, 2026, After Close (Confirmed).
Last Earnings DateMar 26, 2026
Next Earnings DateMay 18, 2026
Ex-Dividend Date―
Financial Position
Inhibikase Therapeutics as a current ratio of 21.70, with Debt / Equity ratio of 0.00%
Current Ratio21.70
Quick Ratio21.70
Debt to Market Cap0.00
Net Debt to EBITDA3.03
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Inhibikase Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Inhibikase Therapeutics EV to EBITDA ratio is -1.36, with an EV/FCF ratio of -2.24.
EV to Sales0.00
EV to EBITDA-1.36
EV to Free Cash Flow-2.24
EV to Operating Cash Flow-2.24
Balance Sheet
Inhibikase Therapeutics has $178.76M in cash and marketable securities with $0.00 in debt, giving a net cash position of $178.76M billion.
Cash & Marketable Securities$178.76M
Total Debt$0.00
Net Cash$178.76M
Net Cash Per Share$1.35
Tangible Book Value Per Share$1.76
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Inhibikase Therapeutics is $6.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.20
Price Target Upside252.27% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast-100.00%
EPS Growth Forecast79.01%